Browse BEX2

Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF04538 Brain expressed X-linked like family
Function

Regulator of mitochondrial apoptosis and G1 cell cycle in breast cancer. Protects the breast cancer cells against mitochondrial apoptosis and this effect is mediated through the modulation of BCL2 protein family, which involves the positive regulation of anti-apoptotic member BCL2 and the negative regulation of pro-apoptotic members BAD, BAK1 and PUMA. Required for the normal cell cycle progression during G1 in breast cancer cells through the regulation of CCND1 and CDKN1A. Regulates the level of PP2A regulatory subunit B and PP2A phosphatase activity.

> Gene Ontology
 
Biological Process -
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BEX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BEX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BEX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3580.609
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8640.627
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.010.994
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2420.693
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3670.74
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0060.471
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2150.69
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4410.644
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.150.868
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.4380.401
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.5320.514
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.590.00258
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BEX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BEX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BEX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BEX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BEX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BEX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBEX2
Namebrain expressed X-linked 2
Aliases DJ79P11.1; brain-expressed X-linked protein 2; Protein BEX2
Chromosomal LocationXq22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BEX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.